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Abstract
Nutritional regulation and drug therapy has been the focus of the current 
obesity epidemic in various countries in the world. Epigenetics is the major 
mechanism for the development of insulin resistance and obesity with unhealthy 
diets, oxidative stress and environmental factors relevant to alterations in 
gene expression with effects on mitochondrial biogenesis, adipose tissue 
lipid metabolism and energy expenditure. Anti-aging genes are involved in 
the regulation of adipogenesis with increased sensitivity to anti-aging gene 
dysfunction associated with adipocyte-neuron interactions compared to other 
cells. Unhealthy diets downregulate adipocyte anti-aging genes associated with 
the development of Non Alcoholic Fatty Liver Disease (NAFLD) with relevance 
to regulation of drug metabolism and delayed pharmacokinetics in the body. 
Evaluation by different methods and techniques to quantify and characterize 
adiposity has been undertaken to obtain a better understanding of adipocyte 
metabolism in obesity but adipocyte analysis is now required to determine 
adipose tissue anti-aging gene expression. Effective drug treatment programs 
cannot be determined in individuals with obesity with defective adipocyte tissue 
gene expression. New drug development needs to be carefully interpreted in 
relation to nutritional intake with drug safety concerns/adverse effects relevant 
to adipogenesis and NAFLD in obesity.
Keywords: Obesity; Metabolism; Drugs; Diet; Anti-aging genes; NAFLD
obesity early in life are of critical understanding to the development 
of hyperinsulinemia which may lead to diabetes and other morbid 
diseases such coronary artery disease and NAFLD [3].
Interests in anti-obese drugs as the major intervention for weight 
loss has been an important strategy for the treatment of obesity. 
Drugs that have been developed for the treatment of obesity are either 
involved in the reduction of energy intake or the increase of energy 
expenditure and their beneficial effects may include improvements in 
glycemic control or psychiatric illness. Interests in the use of obesity 
drugs have increased since safety and use of the drugs for continued 
weight loss (reduced visceral fat stores) have become of concern to 
medical authorities in Western communities [4-9]. Anti-obesity 
drugs that improve insulin resistance, dyslipidemia and the metabolic 
syndrome have not been appropriate to lifestyles, diet and health 
conditions and drug effectiveness have been variable without weight 
loss. Long term treatment of obesity with the use of anti-obese drugs 
particularly centrally active agents has not been achieved with safety 
concerns and withdrawals due to adverse effects that were never 
predicted from clinical trials and drug development. Removal of 
several of these drugs from the market has allowed the introduction of 
other drugs such as gut based hormone treatments which target many 
pathways involved in the regulation of energy balance (Contrave TM 
or Empatic TM). 
Epigenetic modifications involve anti-aging genes with 
increased risk for adipogenesis
The understanding of genetic factors involved in the risk for 
obesity has identified genes that are closely linked to obesity related 
Introduction
The susceptibility of humans to obesity is far higher compared 
with other species and in man favours the deposition of fat. Amongst 
mammals, humans have been reported to have the highest levels of 
fat than any other species and genes and environmental factors such 
as exercise, drugs and diets may predispose humans to obesity. In the 
world obesity has more than doubled since 1980 and in 2014 more 
than 1.9 billion adults (18 years and older) were overweight with 600 
million adults were obese [1]. In the USA obesity trends and rates 
indicate that more than a third of adults (34.9 percent) were obese as 
of 2011 to 2012 [2]. More than two-thirds of adults were overweight 
or obese (68.6 percent) with17 percent of children obese and 31.8 
percent were either overweight or obese. 
In particular, intra-abdominal adipose tissue referred to as 
visceral fat has been associated with the metabolic syndrome and 
obesity. Visceral fat is more metabolically active than peripheral fat 
with the waist-to-hip ratio that identifies patients with excess visceral 
adiposity. Women with a waist-to-hip ratio >0.8 and men with a 
ratio >1.0 are considered to have excess central adiposity that confers 
risk for developing the metabolic syndrome and Non Alcoholic 
Fatty Liver Disease (NAFLD). Morbid obesity is classified as a BMI 
of >35 kg/m2 and severe obesity>40 kg/m2. Adiposity is the body 
fat tissue content and its increase is measured by Body Mass Index 
(BMI). Obese individuals are defined as having a BMI of >30 (BMI 
= weight in kg/m2) [height in m] whereas overweights are defined as 
having a BMI from 25 - 30 kg/m2 and ideal lean individuals to have 
a BMI of 25 kg/m2. The role of adipose tissue and the induction of 
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diseases [10-13]. A single gene effect versus multiple genes effect may 
indicate either the interaction unique to various environments that 
regulate abnormal molecular or cellular events responsible for obesity 
with several hypotheses proposed in relation to the development of 
obesity [14]. The understanding of the development of adipogenesis 
has been the focus of various research groups with unhealthy diets 
that alter DNA methylation (epigenetic), genes and transcription 
factors important to the world-wide obesity epidemic with increased 
risk for adiposity [3,15-17]. Alterations in 400 genes, single gene 
disorders and variants are involved in obesity with particular 
genes (e.g. leptin, melanocortin/Melanocortin 4 receptor, ghrelin, 
neuromedin β, Peroxisome Proliferator Activated Receptor (PPAR), 
and mitochondrial uncoupling proteins) involved in the behaviour, 
metabolism, energy expenditure, taste and appetite of the organism.
The search for specific genes that are sensitive to nutritional 
regulation, oxidative stress, inflammation, endocrine disease, lipid/
glucose metabolism and insulin resistance has been the focus of the 
current obesity epidemic in various developed countries. Epigenetics 
is now considered as an important mechanism for the development 
of obesity and can result from changes in cellular chromatin structure 
without alterations in DNA sequence, including DNA methylation, 
histone modifications and chromatin remodelling. Epigenetic 
modifications in adipocytes are more sensitive compared to other cells 
and are altered by unhealthy diets with increased oxidative stress or 
environmental factors that have the ability to change adipocyte gene 
expression with effects on mitochondrial apoptosis, lipid metabolism 
and energy expenditure. Epigenetic modifications that involve the 
anti-aging genes in the adipose tissue have become important and 
are closely involved with adiponectin release associated with the 
regulation of hepatic lipid metabolism and the induction of NAFLD 
[18].
The increased susceptibility to fat deposition in humans is far 
higher compared with other species and indicate that in man the 
susceptibility to down regulation of the anti-aging genes by Western 
diets and lifestyle alterations (stress, heavy workloads) that alter 
the metabolism of dietary fat in the liver with the development of 
adipogenesis [19]. The connections between the anti-aging gene 
Sirtuin 1 (Sirt 1) and other anti-aging genes such as Klotho, p66Shc 
(longevity protein) and Fork head box proteins (FOXO1/ FOXO3a) 
have been associated with appetite regulation, mitochondrial 
apoptosis and the accelerated aging process with these anti-aging 
genes involved in the regulation of glucose, lipid and amyloid beta 
metabolism that are important to NAFLD and obesity [20]. These 
anti-aging genes have become important and may supersede the 
effects of DNA methylation (epigenetic), genes and transcription 
factors important to the world-wide obesity epidemic with increased 
risk for adiposity. The involvement of the anti-aging gene Sirt 1 in 
the regulation of adipogenesis has been shown [21-23] with adipocyte 
dysfunction associated with excess transfer of fat to liver with NAFLD 
[18,24,25] (Figure 1).
In adipose tissue gene expression profiles of Klotho, p66Shc 
(longevity protein) and Fork head box proteins (FOXO1/ FOXO3a) 
have been completed and indicate down regulation of these genes 
are related to mitochondrial apoptosis, adipogenesis and adipocyte 
differentiation [26-38]. The anti-aging gene Sirt 1 is central to the 
down regulation of these anti-aging genes via its role as a NAD+ 
histone deacetylase and p53 transcriptional dysregulation of these 
genes [18,20]. Bacterial Lipopolysaccarides (LPS) have been shown 
to induce insulin resistance, adipocyte dysfunction with transport of 
LPS lipoproteins to adipose tissue [39-41]. LPS has been shown to 
repress Sirt 1 by defective transcriptional regulation [42] and its role 
in obesity has been clearly documented [39-41]. Diets that are high 
in fat stimulate LPS absorption [42] and LPS in dietary lipoproteins 
induce NAFLD and obesity. The role of Sirt 1 and LPS with relevance 
to adipocyte dysfunction is also relevant to neurodegenerative 
diseases such as Alzheimer’s disease and Parkinson’s disease [43-
45]. LPS interferes with Sirt 1 regulation of neuropeptide Y [20] with 
relevance to the hypothalamus and adipose tissue connections (Figure 
1) associated with disturbed energy metabolism in the adipose tissue 
[46,47].
Methods of visceral fat measurement, adipocyte analysis 
and drug treatment programs
The critical evaluation of different methods and techniques to 
quantify and characterize adiposity has been discussed to obtain a 
better understanding of fat metabolism in obesity. These methods 
include anthropometric techniques, bioelectrical impedance 
analysis, dual energy X-ray absorptiometry, and air displacement 
plethysmography, Ultrasound, CT and MRI. The quantitative 
assessment of intra-abdominal adipose tissue is by CT and MRI and 
represents a direct method of assessing visceral fat deposition in both 
adult with other methods of visceral fat assessment associated with 
imprecision or poor reliability [48]. In the global obesity epidemic a 
direct diagnosis of adipocyte dysfunction needs to be made early in 
life to determine that adipogenesis relevant to defective adipocyte and 
fat metabolism has advanced that cannot be characterized by methods 
of visceral fat assessment. Analysis of adipocytes by flow cytometry 
as well as isolation of adipocytes by flow sorting (Figure 1) has been 
completed [49,50] that now can allow anti-aging gene expression 
analysis of adipocytes [51] from individuals at various ages. 
Figure 1: Anti-aging genes are involved in the regulation of adipogenesis and 
NAFLD with increased sensitivity to anti-aging gene dysfunction and delayed 
drug metabolism in the body. Evaluation by different methods and techniques 
to quantify and characterize adiposity now require adipocyte tissue anti-aging 
gene expression and effective drug programs for global obesity cannot be 
undertaken without healthy diets that activate Sirt 1 regulation of adipose 
tissue and neuron interactions involved in adipose tissue lipid metabolism.
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Long term treatment of obesity with the use of anti-obese drugs 
may not have been successful with over nutrition and LPS involved in 
the corruption of effective anti-obese drug treatment programs [42] 
and withdrawals due to these adverse effects were never predicted from 
clinical trials and drug development. The anti-aging gene expression 
(down regulation) of adipocytes may indicate the presence of LPS or 
Sirt 1 inhibitors in adipose tissues. The consumption of Western diets/
alcohol completely downregulate Sirt 1 with adipocyte isolation and 
analysis required for early diagnosis of adipogenesis defects. Effective 
anti-obese drug treatment programs cannot be determined in 
individuals in the developing/developed world until plasma analysis 
of LPS, Sirt 1 inhibitors [52], fatty acids such as butyric acid, palmitic 
acid (Sirt 1 inhibitors) [3,20] and xenobiotics [53] can be determined 
to assess effect on adipose tissue gene expression in man. The effective 
anti-obese drugs in clinical trials and new drug development need to 
be carefully interpreted in relation to safety concerns/adverse effects 
with relevance to Sirt 1 inhibitors that may be routinely consumed in 
various diets by obese individuals. 
Conclusion
In global communities humans are more susceptible to adiposity 
compared with other species with the increased development of 
overweight individuals, NAFLD and obesity. Drugs that improve 
insulin resistance, dyslipidemia and the metabolic syndrome with 
long term treatment have not been successful with removal of 
various anti-obese drugs from the market. Defective anti-aging genes 
are linked to mitochondrial apoptosis in obesity and indicate that 
these genes are associated with defective hepatic drug clearance and 
metabolism. Lipoaspirates from obese individuals allow assessment 
of anti-aging genes relevant to mitochondrial biogenesis and effective 
drug therapy will be determined by non consumption of inhibitors 
of anti-aging genes (drugs) and consumption of healthy low calorie 
diets that activate adipocyte anti-aging genes.
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